Elon Musk attends ‘Exploring the New Frontiers of Innovation: Mark Read in Conversation with Elon Musk’ session during the Cannes Lions International Festival Of Creativity 2024 – Day Three on June 19, 2024 in Cannes, France.
Marc Piasecki | Getty Images
Tesla shares soared 20% on Thursday, putting the stock on pace for its best day since 2013, following the company’s better-than-expected earnings report.
The company late Wednesday reported revenue of $25.18 billion, which came in just under analysts’ expectations of $25.37 billion, but was up 8% compared to a year earlier. Tesla reported earnings per share of 72 cents adjusted, topping the average analyst estimate of 58 cents.
“We expect this surprising earnings beat to power a strong positive reaction in Tesla shares Thursday, given the degree to which investors have become conditioned to earnings misses from the company,” analysts at JPMorgan wrote in a note.
Tesla’s profit margins in the third quarter were boosted by $739 million in revenue for environmental regulatory credits, which the JPMorgan analysts noted were a “potentially unsustainable driver” of earnings and cash flow.
Automakers are required to obtain a certain amount of regulatory credits every year, and if they can’t meet the target, they can buy credits from other companies. Tesla has excess credits because it only makes electric vehicles.
Tesla earnings also got a boost from FSD, the company’s Full Self-Driving Supervised system. CFO Vaibhav Taneja said on the earnings call that FSD contributed $326 million in revenue in the quarter after Tesla made it available for use in the Cybertruck and added a feature called “Actually Smart Summon.”
CEO Elon Musk said on the call that his “best guess” is that “vehicle growth” will reach 20% to 30% next year, citing “lower cost vehicles” and the “advent of autonomy.” Analysts surveyed by FactSet were expecting delivery growth of about 15% for 2025.
Analysts at Morgan Stanley who recommend buying the stock, called Musk’s 2025 vehicle delivery growth prediction a “maybe.” They set their estimate at 14%.
It “clearly depends on the company’s ability to improve affordability through cheaper model (next gen) introduction, financing offers and improved features,” the Morgan Stanley analysts wrote in a note on Thursday.
The rally on Thursday was second steepest on record and the sharpest since a 24% gain in May 2013. The jump erased Tesla’s loss for the year and left the stock up 3% in 2024, though it still trails the 22% gain for the Nasdaq.
Trust & Will founders, Cody Barbo (CEO), Brian Lamb, and Daniel Goldstein.
Courtesy: Trust & Will
Legal technology company Trust & Will said Tuesday that it has raised $25 million in a Series C funding round. The San Diego-based firm, ranked No. 41 on last year’s CNBC Disruptor 50 list, has now raised $75 million to date.
Trust & Will aims to shake things up in the arcane estate planning industry and make these key wealth preservation and wealth transfer services more accessible to families. Relying on a mix of technology and human oversight, Trust & Will provides legally valid documents that adhere to state guidelines.
The company says the funding will be used to double down on artificial intelligence.
“AI enables families and advisors to plan with greater clarity and confidence,” co-founder and CEO Cody Barbo said in a statement announcing the funding. “By combining technology with human compassion, we’re transforming how people protect and preserve their legacies.”
The new round was led by Moderne Ventures, and includes Northwestern Mutual Future Ventures, UBS Next and Erie Insurance. The most recent publicly available valuation figure for Trust & Will was $169 million, according to PitchBook data as of June 2022. The company told CNBC its valuation is now in the hundreds of millions of dollars, and has increased by more than 5x from its 2020 Series B valuation to its new Series C, but declined to be more specific.
More coverage of the 2024 CNBC Disruptor 50
Trust & Will started when two friends wondered why there weren’t more online options to create a will. Most of their financial lives were already online — banking, taxes, insurance — but wills would require thousands of dollars and talking to a lawyer. Or a barebones online template that doesn’t leave room for customization or questions.
Its closest competitors, LegalZoom and Rocket Lawyer, focus on a broader variety of services. There’s also FreeWill.com, which offers free templates for people to fill out.
A recent annual report from Trust & Will found that although 83% of Americans believe estate planning is important, only 31% have a will, and 55% have no plan at all. Today, the company says it has helped hundreds of thousands of families create estate plans and settle probate to solve for that problem, and over one million Americans have started their legacy planning on the platform.
The company works directly with individuals and through partnerships with financial institutions. Trust & Will’s partnerships include Bank of America, USAA and Navy Federal. To get the word out to the general public, the company recently hired its first celebrity brand ambassadors, Super Bowl Champion Matthew Stafford and his wife, podcaster Kelly Stafford, to talk about their estate planning experience in a national TV commercial. It also recently became the official estate planning partner to two professional sports teams, the Los Angeles Kings and San Diego Wave.
“Every family deserves access to estate planning, and every professional deserves tools that simplify the process while delivering exceptional results,” Barbo stated in the release. “This Series C funding is more than a company milestone — it’s a step toward transforming estate planning into an essential service that touches every family’s life and legacy.”
Sign up for our weekly, original newsletter that goes beyond the annual Disruptor 50 list, offering a closer look at list-making companies and their innovative founders.
Hinge Health, a provider of digital physical therapy services, filed to go public on Monday, the latest sign that the IPO market is starting to crack open.
Hinge Health uses software to help patients treat musculoskeletal injuries, chronic pain and carry out post-surgery rehabilitation remotely. The company’s revenue last year increased 33% to $390 million, according to its prospectus, and its net loss for the year narrowed to $11.9 million from $108.1 million a year earlier.
The IPO market has been quiet across the tech sector for the past three years, but within digital health it’s been almost completely silent, as companies have struggled to adapt to an environment of muted growth following the Covid-19 pandemic. No digital health companies held IPOs in 2023, according to a report from Rock Health, and last year the only notable offerings were Waystar, a health-care payment software vendor, and Tempus AI, a precision medicine company.
“We have many decades of work ahead,” Hinge Health CEO Daniel Perez said in the filing Monday. “We hope you join us on this journey.”
The company plans to trade on the New York Stock Exchange under the ticker symbol “HNGE.”
Perez and Gabriel Mecklenburg, Hinge Health’s chairman, co-founded the company in 2014 after experiencing personal struggles with physical rehabilitation, according to the company’s website.
Members of Hinge Health can access virtual exercise therapy and an electrical nerve stimulation device called Enso. The company claims its technology can help users improve their pain, reduce the need for surgery and cut down health-care costs.
The San Francisco-based company has raised more than $1 billion from investors including Tiger Global and Coatue Management, and it boasted a $6.2 billion valuation as of October 2021. The biggest outside shareholders are venture firms Insight Partners and Atomico, which own 19% and 15% of the stock, respectively, according to the filing.
Hinge Health’s dual class stock structure gives each share of Class B common stock 15 votes. Almost all of the Class B shares are owned by the founders and top investors.
Employees across more than 2,250 organizations, including Morgan Stanley, Target and General Motors, can access Hinge Health’s offerings. The company had more than 532,000 members as of Dec. 31, and more than 20 million people are eligible to enroll, the filing said.
People wait in line for t-shirts at a pop-up kiosk for the online brokerage Robinhood along Wall Street after the company went public with an IPO earlier in the day on July 29, 2021 in New York City.
Spencer Platt | Getty Images
It was a bad day for tech stocks, and a brutal one for fintech.
As the Nasdaq suffered its steepest decline since 2022, some of the biggest losers were companies that sit at the intersection of Wall Street and Silicon Valley.
Stock trading app Robinhood tumbled 20%, bitcoin holder Strategy fell 17% and crypto exchange Coinbase lost 18%. Much of the slide in those three stocks was tied to the drop in bitcoin, which fell almost 5%, continuing its downward trajectory. The price of the leading cryptocurrency is now down 19% in the past month, falling after a big-post election pop in late 2024.
Beyond the crypto trade, online lenders and payments companies also fell more than the broader market. Affirm, which popularized buy now, pay later loans, dropped 11%, as did SoFi, which offers personal loans and mortgages. Shopify, which provides payment technology to online retailers, fell more than 7%.
JPMorgan Chase fintech analysts on Monday highlighted declining consumer confidence as a potential challenge for companies that rely on consumer spending for growth. In late February, the Conference Board’s Consumer Confidence Index slipped to 98.3 for the month, down nearly 7%, the largest monthly drop since August 2021. Walmart recently reported a shift away from discretionary purchases, underscoring the potential trouble.
“Our universe has modestly outperformed the S&P 500 since the election, but sentiment has soured of late on declining consumer confidence and signs of slowing discretionary spend,” the JPMorgan analysts wrote.
The fintech selloff follows a strong rally in the fourth quarter, driven by Fed rate cut expectations and hopes for a more favorable regulatory environment under the Trump administration.